DPX

Annual Financial Statements Update for the Year Ended October 31, 2023

Retrieved on: 
Wednesday, February 21, 2024
Acquisition, Person, Requirement, News, File, FRA, IAS, Ontario Securities Commission, OSC, DMCL, Documentation, National Policy, National instrument, Policy, DPX, IAS 10, Bank statement, Audit

Under National Instrument 51-102, the Required Filings are required to be made not later than February 28, 2024 (the " Filing Deadline").

Key Points: 
  • Under National Instrument 51-102, the Required Filings are required to be made not later than February 28, 2024 (the " Filing Deadline").
  • The Company believes that this acquisition constitutes a major purchase of assets that must be reported in its financial statement in accordance with IAS 10.
  • The Company continues to work to complete the Company's annual financial statements, and expects to file the Required Filings by March 30, 2024, and will issue a news release once the Required Filings have been filed.
  • The Company's auditors have also made significant efforts to complete its audit of the annual financial statements.

PowerScan 9600 DPX Series: Unleashing Unsurpassed DPM Traceability

Retrieved on: 
Thursday, January 11, 2024
RGB, STAR, DPM, Electronics, DPX, Algorithm, Direct part marking, Acquisition, Health, IA Financial Group, WIP, IP67, IP65

BOLOGNA, Italy, Jan. 11, 2024 /PRNewswire-PRWeb/ -- Datalogic, a global leader in the automatic data capture and factory automation markets, is thrilled to announce the launch of the revolutionary PowerScan™ 9600 DPX Series. As the world of manufacturing evolves, traceability has become a critical aspect of production processes across various industries, including automotive, electronics, and healthcare. The ability to track products at a granular level ensures safer products, continuous improvements, and faster issue resolution. To address these needs, Datalogic is proud to introduce the PowerScan 9600 DPX Series, an industrial handheld scanner designed to excel in Direct Part Marking (DPM) applications. The new range of scanners offers several key features and solutions for businesses facing traceability challenges.

Key Points: 
  • Datalogic is thrilled to introduce the PowerScan™ 9600 DPX Series, an industrial handheld scanner designed for Direct Part Marking (DPM) applications.
  • To address these needs, Datalogic is proud to introduce the PowerScan 9600 DPX Series, an industrial handheld scanner designed to excel in Direct Part Marking (DPM) applications.
  • The PowerScan 9600 DPX Series represents the pinnacle of reliability, modularity, and efficiency in DPM applications.
  • For businesses seeking to enhance their traceability capabilities, the PowerScan 9600 DPX Series is the answer.

Tops Launches Tops DPX, a One-Stop Solution for Streamlined Orthodontic Patient Engagement

Retrieved on: 
Monday, October 2, 2023
Health, Technology, Practice Management, Other Technology, Other Health, Software, Dental, Communication, Patient, Family, DPX, Dentistry, Orthodontics

Orthodontic practices now have a single solution to elevate patient engagement and provide streamlined, personalized care.

Key Points: 
  • Orthodontic practices now have a single solution to elevate patient engagement and provide streamlined, personalized care.
  • Tops, a leader in orthodontic practice management software, today proudly debuted Tops DPX , a fully integrated digital patient engagement platform designed to simplify communication.
  • In one platform, Tops DPX integrates several essential communication services, including texting, appointment reminders, patient reviews, and email messaging.
  • This new feature comes as a strategic move to provide orthodontic practices with a consolidated, cost-effective solution to enhance both staff efficiency and patient satisfaction.

EnerSys® Accelerates 5G Small Cell Deployment with DPX Distributed Power Transport System

Retrieved on: 
Tuesday, September 26, 2023
Utilities, Manufacturing, Alternative Energy, Energy, Construction & Property, Building Systems, Other Manufacturing, Mobile, NYSE, Las Vegas Convention Center, ENS, DPX, Mobile World Congress, Safety, Renewable energy, EnerSys

The DPX Distributed Power Transport System is being featured in the EnerSys booth, #818, at the Mobile World Congress being held at the Las Vegas Convention Center, September 26-28.

Key Points: 
  • The DPX Distributed Power Transport System is being featured in the EnerSys booth, #818, at the Mobile World Congress being held at the Las Vegas Convention Center, September 26-28.
  • “5G small cell deployment is often delayed or not economically feasible because providing power to each small cell requires a permit as well as coordination with the electrical utility.
  • Our DPX solution addresses these hurdles by using a single grid tap to power up to 10 small cell nodes.”
    The DPX Distributed Power Transport System supplies power to 5G small cells located up to 1 mile away.
  • A single DPX system installation can energize up to 10 nodes that are using higher power small cell radios, or up to 40 nodes using low power radios.

IMV Inc. Announces Update on CCAA Proceedings and Sales and Investment Solicitation Process

Retrieved on: 
Wednesday, July 26, 2023
Research, Public Policy, Government, Healthcare Reform, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Canada, Telephone, Court, IMV, Monitor, CCAA, Patient, DPX, Pharmaceutical industry, Risk management

As previously disclosed, IMV initiated the CCAA proceedings on May 1, 2023, to facilitate the restructuring of the Company with the goal of implementing a transaction.

Key Points: 
  • As previously disclosed, IMV initiated the CCAA proceedings on May 1, 2023, to facilitate the restructuring of the Company with the goal of implementing a transaction.
  • The Company appreciates the ongoing support of its employees, shareholders, patients, and other stakeholders as it navigates the CCAA proceedings.
  • All enquiries regarding the CCAA proceedings should be directed to the Monitor via email at: [email protected] or telephone: 1-416-649-8129 or 1-833-981-8009.
  • Information about the CCAA proceedings, including copies of all court orders, Monitor’s Report and the SISP, are available on the Monitor’s website: http://cfcanada.fticonsulting.com/imv/default.htm

Deluxe and ECHO Health Form JV to Bring Advanced Payables Solutions to the Middle-Market

Retrieved on: 
Tuesday, May 2, 2023
Payments, Professional Services, Technology, Fintech, Software, Partnership, Digital, Health, ECHO, AP, ACH, DPX, JV, Risk, Fraud, NYSE, Online shopping, Mobile phone, Deluxe

Deluxe (NYSE: DLX) and ECHO Health have joined forces to create DPX Payments, a joint venture to deliver advanced payables offerings to the large and underserved middle-market.

Key Points: 
  • Deluxe (NYSE: DLX) and ECHO Health have joined forces to create DPX Payments, a joint venture to deliver advanced payables offerings to the large and underserved middle-market.
  • Deluxe and Echo first partnered in 2019 with the launch of the Medical Payment Exchange, which, along with the existing Deluxe Payment Exchange (DPX), is growing rapidly, processing more than $20 billion in payments annually.
  • The joint venture will leverage the extensive network of businesses with existing relationships with Deluxe enabling significant scale over time.
  • We believe that this joint venture will pave the way for even more significant growth opportunities for both Deluxe and ECHO Health."

IMV Initiates Restructuring Proceedings Under the CCAA to Complete the Review of its Strategic Alternatives

Retrieved on: 
Monday, May 1, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Exercise, IMV, Toronto Stock Exchange, Clinical trial, Cancer, CCAA, DPX, Sale, Nova Scotia Supreme Court, Hematological Cancer Research Investment and Education Act, Patient, Laboratory, Bankruptcy Code, Court, TSX, Monitor, News, Pharmaceutical industry

The Company will seek the recognition of the Initial Order in the United States by filing a petition commencing proceedings under the Chapter 15 of the United States Bankruptcy Code.

Key Points: 
  • The Company will seek the recognition of the Initial Order in the United States by filing a petition commencing proceedings under the Chapter 15 of the United States Bankruptcy Code.
  • The Court has appointed FTI Consulting Canada Inc. to serve as the Monitor in the CCAA proceedings and to assist the Company with its restructuring efforts and report to the Court during the restructuring.
  • At this time, the Company expects that it will have sufficient funds to complete its CCAA proceedings and potential restructuring.
  • Further news releases will be provided on an ongoing basis throughout the CCAA proceedings as required by law or otherwise as may be determined necessary by the Company or the Court.

IMV Inc. Announces Changes to Its Board of Directors

Retrieved on: 
Monday, March 27, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, IMV, Doctor of Philosophy, LSF, Policy, MBA, DPX, Hematological Cancer Research Investment and Education Act, Tilley, CTI, TSX, Management

IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced changes to its board of directors as Shermaine Tilley, Ph.D., MBA has resigned from the Board of Directors ("Board") of the Company, effective immediately.

Key Points: 
  • IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced changes to its board of directors as Shermaine Tilley, Ph.D., MBA has resigned from the Board of Directors ("Board") of the Company, effective immediately.
  • Dr. Tilley, Managing Partner at CTI Life Sciences Fund (“CTI LSF”), was originally appointed to the IMV Board in 2016 as a representative from CTI LSF following their initial investment in IMV.
  • Dr. Tilley’s resignation arose due to policy changes surrounding board positions at CTI LSF and she will remain IMV’s point of contact at CTI LSF.
  • “On behalf of the Board of Directors, I want to thank Shermaine for her service and commitment to IMV during the last seven years.

IMV Inc. Announces Strategic Update as well as Fourth Quarter and Full Year 2022 Financial and Operational Results

Retrieved on: 
Thursday, March 16, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, DPX, TSX, Annual general meeting, Pembrolizumab, Exercise, EDGAR, Western University, LG Chem, Acquisition, Cancer, Hematology, Workforce, Lymph, Chairperson, Indian stock exchange, SVP, Natural killer T cell, APC, Immune system, Immunotherapy, Acceleration, AACR, Hematological Cancer Research Investment and Education Act, Webcast, MD, Stonegate, Peptide, Patient, SITC, Sanofi, FDA, EST, DLBCL, IMV, Research, Environment, SEDAR, Ovarian cancer, Bristol Myers Squibb, NK, Pharmaceutical industry, Medical imaging, Nursing, Vaccine, Cryptocurrency, Antigen

Patients need improved treatments for cancer, particularly in the refractory setting,” said Andrew Hall, Chief Executive Officer at IMV.

Key Points: 
  • Patients need improved treatments for cancer, particularly in the refractory setting,” said Andrew Hall, Chief Executive Officer at IMV.
  • Restructuring: In September 2022, IMV completed a strategic reorganization to reduce future cash needs and further streamline the organizational focus.
  • Management will hold a conference call and webcast on Thursday, March 16, 2023, at 8:00 a.m. EST to discuss the Company’s 2022 fourth quarter and fiscal year-end financial and operational results.
  • The webcast will be recorded and will then be available on the IMV website for 30 days following the call.

IMV Inc. to Announce Fourth Quarter and Fiscal Year 2022 Results and Host a Conference Call and Webcast on March 16, 2023

Retrieved on: 
Thursday, March 9, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Hematological Cancer Research Investment and Education Act, DPX, Webcast, IMV, TSX, Pharmaceutical industry

ET to discuss the company’s 2022 fourth quarter and fiscal year-end financial and operational results.

Key Points: 
  • ET to discuss the company’s 2022 fourth quarter and fiscal year-end financial and operational results.
  • Financial analysts are invited to join the conference call by registering at this link prior the call to receive their individual dial-in information.
  • Other interested parties will be able to access the live audio webcast at this link: https://ir.imv-inc.com/events-and-presentations .
  • The webcast will be recorded and will then be available on the IMV website for 30 days following the call.